Profile
NAVB VRTX REGN VRNA ARGX SGEN
Company Name Navidea Biopharmaceuticals, Inc. Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Verona Pharma plc argenx SE Seagen Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $10.01K $122.53B $81.42B $72.68B $51.58B $43.15B
Employees 0.01K 6.10K 15.16K 0.21K 1.60K 3.26K
CEO Craig A. Dais CPA Reshma Kewalramani Leonard S. Schleifer David S. Zaccardelli Timothy Van Hauwermeiren David R. Epstein
Ratings
NAVB VRTX REGN VRNA ARGX SGEN
Quant Rating Score 2 4 4 1 4 3
Quant Rating Sell Buy Buy Strong Sell Buy Neutral
Trading
NAVB VRTX REGN VRNA ARGX SGEN
Last Close $0.0001 $434.02 $704.31 $106.91 $929.61 $228.74
High 52 $0.01 $513.76 $788 $106.91 $929.61 $228.74
Low 52 - $366.54 $482.92 $37.86 $532.27 $228.74
Price vs. 52 Week High -99 % -15.52 % -10.62 % 0 % 0 % 0 %
Price vs. 52 Week Low 0 % 18.41 % 45.84 % 182.38 % 74.65 % 0 %
Total Return
NAVB VRTX REGN VRNA ARGX SGEN
1 Month Return 0 % 4.13 % 21.84 % 0 % 10.19 % 0 %
3 Month Return -80 % 11.32 % 22.74 % 1.06 % 40.57 % 0 %
6 Month Return -85.71 % -1.06 % 18.51 % 49.92 % 64.35 % 0 %
9 Month Return -85.71 % -6.08 % 3.57 % 66.4 % 45.48 % 0 %
YTD Return 0 % 7.78 % -1.13 % 130.21 % 51.16 % 0 %
1 Year Return -90 % -3.12 % -5.41 % 180.68 % 61.8 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
NAVB VRTX REGN VRNA ARGX SGEN
Dividend Yield Percentage (TTM) - - 0.45 % - - -
Dividend Paid and Capex Coverage Ration (TTM) -23.02 % 9.76 % 3.92 % -147.93 % 65.28 % -5.87 %
Dividend Per Share (TTM) - - 3.52 % - - -
Payout Ratio (TTM) - - 8.22 % - - -
Growth
NAVB VRTX REGN VRNA ARGX SGEN
Asset Growth -34.21 % 7.41 % 53.91 % -1.21 %
Gross Profit Growth -151.19 % 1.16 % - 22.93 %
Revenue Growth -87.65 % 0.99 % - 24.65 %
Revenue 3 Year 20.98 % 20.64 % -15.89 % 91.56 %
Revenue 5 Year -99 % 73.64 % - 215.48 %
Revenue 10 Year -85.93 % 285.02 % - 494.04 %
EBIT Growth -20.28 % 9.09 % -131.37 % -3.48 %
Net Income Growth -29.38 % 2.09 % -224.78 % 9.51 %
Net Income 3 Yeari Growth Per Share 31.99 % 6.32 % -148.34 % -763.59 %
Net Income 5 Yeari Growth Per Share -105.58 % 31.91 % 25.82 % -276.93 %
Net Income 10 Yeari Growth Per Share 91.21 % 680.22 % -35.51 % -624.16 %
Operating Income Growth -16.5 % -7.46 % -133.02 % 10.13 %
Operating Cash Flow Growth (CFG) 12.05 % - -143.33 % 9.07 %
Operating 3 Year CFG 52.88 % -100 % -170.73 % -147.99 %
Operating 5 Year CFG -104.19 % -100 % 54.81 % -195.86 %
Operating 10 Year CFG 93.66 % -100 % 40.15 % -2622.09 %
EPS Growth -47.5 % 5.31 % -214.81 % 10.81 %
EPS Diluted Growth -40 % 8.19 % -208.93 % 10.81 %
Book Value Per Share -1403.47 % 32.88 % -22.82 % -9.83 %
Share Holder 3 Year Equity Growth Per Share -156.65 % 41.21 % 1.82 % 33.72 %
Share Holder 5 Year Equity Growth Per Share -120.41 % 191.63 % -24.45 % 220.81 %
Share Holder 10 Year Equity Growth Per Share -1.32 % 842.11 % -71.86 % 691.19 %
Dividend Per Share Growth - - - -
Dividend 3 Year Growth Per Share - - - -
Dividend 5 Year Growth Per Share - - - -
Dividend 10 Year Growth Per Share -100 % - - -
Debt Growth 224.99 % 0.06 % 139.05 % -23.28 %
Free Cash Flow Growth 11.1 % - -144.48 % 3.67 %
Updated On 31 Dec 2022 31 Dec 2025 31 Dec 2024 31 Dec 2022
Profitability
NAVB VRTX REGN VRNA ARGX SGEN
Gross Profit Margin TTM -259.4 % 86.28 % 86.27 % 95.15 % 65.82 % 79.1 %
Return on Assets TTM -347.18 % 14.78 % 11.11 % -11.01 % 15.06 % -16.61 %
Return on Equity TTM 355.34 % 21.81 % 14.83 % -30.05 % 18.96 % -20.8 %
Return on Capital Employed TTM 252.25 % 19.59 % 10.3 % -8.31 % 5.04 % -21.46 %
Net Income Per EBT TTM 100 % 82.61 % 86.12 % 111.64 % 237.3 % 101.33 %
EBT Per Ebit TTM 108.02 % 111.4 % 146.19 % 130.36 % 147.38 % 98.26 %
EBIT Per Revenue TTM -21402.08 % 34.06 % 24.95 % -25.86 % 13.47 % -31.24 %
Cash Flow To Debt Ratio TTM -368.96 % 202.64 % 184 % -29.66 % 932.29 % -1043.73 %
Receivables Turnover TTM 104.21 6.02 2.5 1.93 1.91 3.91
Payables Turnover TTM 0.09 0.4 2.1 2.37 0.9 1.97
Inventory Turnover TTM 0.43 0.99 0.62 0.94 2.26 0.96
Fixed Asset Turnover TTM 42.18 % 388.59 % 280.11 % 6536.22 % 5009.77 % 665.41 %
Asset Turnover TTM 1.5 % 47.15 % 35.36 % 29.27 % 31.97 % 53.41 %
Operating Cash Flow Per Share TTM -0.31 14.55 48.39 -0.85 5.67 -2.46
Free Cash Flow Per Share TTM -0.32 13.06 39.66 -0.85 5.58 -2.88
Cash Per Share TTM 6.8 % 2459.7 % 8362.68 % 511.43 % 5536.58 % 939.52 %
Operating Cash Flow Sales Ratio TTM -13688.19 % 31.71 % 34.71 % -43.23 % 17.54 % -23.12 %
Free Cash Flow Operating Cash Flow Ratio TTM 104.34 % 89.76 % 81.96 % 100.75 % 98.47 % 117.04 %
Cash Flow Coverage Ratios TTM -368.96 % 202.64 % 184 % -29.66 % 932.29 % -1043.73 %
Price To Free Cash Flows Ratio TTM - 36.72 19.95 -995.27 129.37 -81.26
Price To Operating Cash Flows Ratio TTM - 32.86 16.2 -126.33 146.05 -93.1
Price Cash Flow Ratio TTM - 32.86 16.2 -126.33 146.05 -93.1
Income Statement (TTM)
NAVB VRTX REGN VRNA ARGX SGEN
Revenue $0B $12.07B $14.34B $0.03B $2.19B $1.96B
Gross Profit $-0B $10.27B $12.24B $0.03B $1.96B $1.55B
Gross Profit Ratio -259.4% 85.03% 85.35% 93.89% 89.62% 79.1%
EBITDA $-0.01B $4.97B $5.82B $-0.12B $0.11B $-0.62B
Net Income $-0.02B $3.95B $4.5B $-0.14B $0.83B $-0.61B
EPS Diluted -0.56 15.32 41.48 -1.73 12.78 -3.3
Balance Sheet (MRQ)
NAVB VRTX REGN VRNA ARGX SGEN
Long Term Debt $0B $3.8B $2.71B $0.12B $0.03B $0.04B
Total Liabilities $0.01B $7.48B $9.3B $0.27B $0.7B $0.87B
Total Equity $-0.01B $18.67B $31.26B $0.2B $5.5B $2.8B
Total Investments $0B $7.33B $15.75B $0.02B $1.93B $1.42B
Total Debt $0B $3.88B $2.71B $0.12B $0.04B $0.04B
Total Assets $0B $26.14B $40.56B $0.47B $6.2B $3.67B
Cash Flow Statement (TTM)
NAVB VRTX REGN VRNA ARGX SGEN
Net Income $-0.02B $3.95B $4.5B $-0.17B $0.83B $-0.61B
Inventory $-0B $-0.52B $-0.28B $-0.01B $-0.1B $-0.23B
Dividends Paid $0B $0B $-0.37B $0B $0B $0B
Operating Cash Flow $-0.01B $3.63B $4.98B $-0.12B $-0.08B $-0.45B
Capital Expenditure $-0B $-0.44B $-0.9B $-0B $-0.07B $-0.08B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 23.82
AARD Aardvark Therapeutics, Inc. Common Stock 12.1
ABCL AbCellera Biologics Inc. 3.1
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.01
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 2.51
ABPWW 0.0131
ABSI Absci Corporation 2.55
ABUS Arbutus Biopharma Corporation 3.98
ABVC ABVC BioPharma, Inc. 1.67
ABVX Abivax SA American Depositary Shares 124.99
ACAD ACADIA Pharmaceuticals Inc. 22.03
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 6.91
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 4.2
ACIU AC Immune SA 2.99
ETFs With Exposure to NAVB
Ticker ETF Name Weight Percentage Price
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 149.23
Unlock